8-K: ResMed Reports Strong Q4 and Full Year 2025 Results, Boosts Quarterly Dividend by 13%

ResMed Inc. announced robust financial performance for the fourth quarter and full fiscal year 2025, marked by significant revenue and profit growth and an increased quarterly cash dividend.

Summary

• Fourth Quarter 2025 revenue increased by 10% to $1.3 billion, or 9% on a constant currency basis, compared to the prior year period.
• Full Year 2025 revenue increased by 10% to $5.1 billion, or 10% on a constant currency basis, compared to the prior year period.
• Income from operations for Q4 2025 increased by 19%, with non-GAAP income from operations also up 19%.
• Income from operations for Full Year 2025 increased by 28%, with non-GAAP income from operations up 19%.
• Operating cash flow for Q4 2025 was $539 million, and for Full Year 2025 was $1.8 billion.
• Diluted earnings per share for Q4 2025 was $2.58 (non-GAAP $2.55), representing a 30% increase (non-GAAP 23%).
• Diluted earnings per share for Full Year 2025 was $9.51 (non-GAAP $9.55), representing a 37% increase (non-GAAP 24%).
• The board of directors declared a quarterly cash dividend of US $0.60 per share, a 13% increase.
• Acquired VirtuOx, a leading independent diagnostic testing facility for sleep, respiratory, and cardiac conditions.
• Paid $78 million in dividends to shareholders and repurchased 419,000 shares for $100 million during the fourth quarter as part of capital management.

Sentiment

Score: 9

Explanation: The filing reports exceptionally strong financial results across all key metrics, including revenue, profit, EPS, and cash flow, coupled with a significant dividend increase and a strategic acquisition. The tone is highly positive, indicating robust business momentum and effective capital management.

Positives

• Strong revenue growth of 10% year-over-year for both the fourth quarter and the full fiscal year 2025.
• Significant increase in income from operations: 19% for Q4 and 28% for the full year.
• Gross margin improved by 230 basis points in Q4 to 60.8% (non-GAAP 61.4%) and by 270 basis points for the full year to 59.4% (non-GAAP 60.0%), driven by procurement, manufacturing, and logistics efficiencies.
• Robust operating cash flow of $539 million in Q4 and $1.8 billion for the full year, indicating strong cash generation.
• Diluted earnings per share saw substantial growth: 30% in Q4 and 37% for the full year.
• Quarterly cash dividend increased by 13% to $0.60 per share, demonstrating commitment to shareholder returns.
• Strategic acquisition of VirtuOx enhances capabilities in at-home diagnostic services, supporting earlier patient engagement and connected care.
• Selling, general, and administrative expenses improved to 19.7% of revenue in Q4, down from 19.8% in the prior year period, indicating improved efficiency.
• Continued investment in innovation and scaling digital health capabilities to expand access to care globally.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to materially differ from projections.
• Potential risks include those related to future revenue or earnings, expenses, new product development and launches, new markets for products, integration of acquisitions, supply chain disruptions, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions on the business.

Future Outlook

Will continue to invest in innovation, scale digital health capabilities, and partner with patients, providers, payers, and policymakers to ensure more people around the world have access to the care they need to sleep better, breathe better, and live longer and healthier lives.

Management Comments

• "Our strong finish to fiscal year 2025 reflects ongoing momentum across our business, driven by robust global demand for our market-leading sleep and breathing health devices, as well as our expanding digital health ecosystem." Mick Farrell, Chairman and CEO.
• "In the fourth quarter, we delivered 10% headline revenue growth, 230 basis points in non-GAAP gross margin expansion, and 23% non-GAAP EPS growth. These results are a testament to the value that our best-in-class solutions deliver to our customers, and the unwavering dedication of our global team." Mick Farrell, Chairman and CEO.
• "Our connected care platform continues to set the standard for digital health innovation, empowering millions of people to take control of their sleep and breathing health with hardware, software and healthcare solutions delivered in their own homes." Mick Farrell, Chairman and CEO.

Industry Context

The results indicate strong demand for sleep and breathing health devices and digital health solutions, aligning with a broader trend of increasing focus on chronic disease management and home-based care. ResMed's emphasis on its connected care platform and digital health innovation positions it well within the evolving healthcare technology landscape. The acquisition of VirtuOx further strengthens its position in at-home diagnostic services, a growing segment of the healthcare industry.

Corporate Governance

Stakeholder Impact

• Shareholders benefit from increased dividends ($0.60 per share, up 13%), strong earnings growth, and share repurchases ($100 million in Q4), indicating enhanced shareholder value.
• Customers benefit from continued investment in innovation, an expanding digital health ecosystem, and the acquisition of VirtuOx, which aims to support patients earlier in their journey and deliver more connected care.
• Employees may benefit from increased employee-related costs mentioned in SG&A expenses, suggesting ongoing investment in the workforce.
• Healthcare Providers and Homecare Companies benefit from ResMed's solutions and the VirtuOx acquisition, which aims to simplify and connect care delivery.

Next Steps

• Continue to invest in innovation.
• Scale digital health capabilities.
• Partner with patients, providers, payers, and policymakers to expand access to care.
• Webcast of conference call for Q4 2025 results on July 31, 2025, at 1:30 p.m. U.S. Pacific Time.
• Payment of quarterly cash dividend on September 18, 2025.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with double-digit growth in revenue, operating profit, and EPS for both the quarter and the full fiscal year. The significant increase in the quarterly dividend, strong operating cash flow, and strategic acquisition of VirtuOx indicate robust business health, effective capital allocation, and a clear growth strategy in the expanding sleep and breathing health market. These factors suggest strong potential for continued shareholder value creation.

Keywords

ResMed, RMD, earnings, financial results, Q4 2025, fiscal year 2025, revenue, profit, EPS, dividend, sleep apnea, COPD, digital health, medical devices, healthcare, VirtuOx, acquisition, cash flow, NYSE, ASX